Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Capital Expenditures (2016 - 2025)

Perspective Therapeutics' Capital Expenditures history spans 16 years, with the latest figure at $39000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 99.9% year-over-year to $39000.0; the TTM value through Sep 2025 reached -$39.6 million, down 202.08%, while the annual FY2024 figure was $72000.0, 300.0% up from the prior year.
  • Capital Expenditures for Q3 2025 was $39000.0 at Perspective Therapeutics, up from $36000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $39.8 million in Q3 2024 and bottomed at -$39.7 million in Q4 2024.
  • The 5-year median for Capital Expenditures is $54000.0 (2021), against an average of $39368.4.
  • The largest YoY upside for Capital Expenditures was 4413.43% in 2024 against a maximum downside of 4857.38% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$86000.0 in 2021, then surged by 275.58% to $151000.0 in 2022, then plummeted by 739.07% to -$965000.0 in 2023, then plummeted by 4016.89% to -$39.7 million in 2024, then soared by 100.1% to $39000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Capital Expenditures are $39000.0 (Q3 2025), $36000.0 (Q2 2025), and $9000.0 (Q1 2025).